Yesterday, at IDiBE we welcomed our External Advisory Board (EAB) to evaluate our strategic lines and their scientific impact.
Our EAB is composed of internationally renowned researchers, including Banafshé Larijani (Director of the Centre for Therapeutic Innovation at the University of Bath), Mabel Loza (Director of CiMUS — Center for Research in Molecular Medicine and Chronic Diseases — and of the Kærtor Foundation), Juliette Legler (Head of the Division of Toxicology at the Institute for Risk Assessment Sciences, Utrecht University), and Eduard Montanya (Scientific Director of CIBERDEM). We send our warm regards to Banafshé, who had to excuse herself, despite already being in Spain, due to a personal loss.
During the day, IDiBE’s research groups presented some of their most innovative projects in areas such as molecular oncology, sensory neurobiology, and the valorization of agricultural by-products for advanced applications. The visit also included an institutional meeting with Ángel Antonio Carbonell Barrachina, Vice-Rector for Research and Knowledge Transfer, to demonstrate Miguel Hernández University’s commitment to health research.
IDiBE’s director, Antonio Ferrer Montiel, emphasized the importance of the visit: “Having a high-level external evaluation is essential to ensure scientific excellence and to continue aligning our goals with major societal and biomedical challenges. Additionally, one of our objectives is to obtain the María de Maeztu Seal of Excellence, and this kind of guidance can be key to achieving it.”
The EAB’s conclusions will serve as a foundation to strengthen the institute’s strategic plan and reinforce its role as a benchmark in health biotechnology both in Spain and internationally.